Apremilast Study in Children with Active Juvenile Psoriatic Arthritis
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Apremilast in Children From 5 to Less Than 18 Years of Age With Active Juvenile Psoriatic Arthritis (PEAPOD) - PEAPOD A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Evalua ...